RCM
BNTC icon

RA Capital Management’s Benitec Biopharma BNTC Stock Holding History

RA Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.7M Hold
1,850,000
– – 0.21% 59
2025
Q4 		$24.9M Buy
+1,850,000
New +$25.6M 0.26% 46
2015
Q4 		– Sell
-551
Closed -$864K – 40
2015
Q3 		$864K Buy
+551
New +$1.03M 0.12% 44

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

RA Capital Management's BNTC Position: Q1 2026 in Review

RA Capital Management held its Benitec Biopharma (BNTC) position steady in Q1 2026 at 1,850,000 shares worth $19.7M. The position accounts for 0.21% of the portfolio, ranked #59.

RA Capital Management first reported a position in BNTC in Q3 2015 and has held it in 3 quarters since. The position peaked at $24.9M in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • RA Capital Management held 1,850,000 shares of Benitec Biopharma worth $19.7M as of Q1 2026.
  • RA Capital Management left its Benitec Biopharma share count unchanged in Q1 2026.
  • Benitec Biopharma made up 0.21% of RA Capital Management's portfolio in Q1 2026, its #59 holding.
  • RA Capital Management first reported a position in Benitec Biopharma in Q3 2015 and has held it in 3 quarters since.
  • RA Capital Management's Benitec Biopharma position peaked at $24.9M in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.